DK2350047T3 - p38-MAP-KINASEINHIBITORER - Google Patents

p38-MAP-KINASEINHIBITORER

Info

Publication number: DK2350047T3
Authority: DK; Denmark
Prior art keywords: kinase inhibitors; map kinase; map; inhibitors; kinase
Prior art date: 2008-10-02

Application number

DK09736271.9T

Other languages

English (en)

Inventor

Kazuhiro Ito

Peter Strong

William Garth Rapeport

John King-Underwood

Jonathan Gareth Williams

Stuart Thomas Onions

Peter John Murray

Catherine Elisabeth Charron

Original Assignee

Respivert Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-02

Filing date

2009-10-02

Publication date

2013-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019929&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2350047(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-10-02 Application filed by Respivert Ltd filed Critical Respivert Ltd

2013-09-30 Application granted granted Critical

2013-09-30 Publication of DK2350047T3 publication Critical patent/DK2350047T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

DK09736271.9T 2008-10-02 2009-10-02 p38-MAP-KINASEINHIBITORER DK2350047T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0818033.3A GB0818033D0 (en)	2008-10-02	2008-10-02	Novel compound
PCT/GB2009/051303 WO2010038085A2 (en)	2008-10-02	2009-10-02	P38 mapk kinase inhibitor

Publications (1)

Publication Number	Publication Date
DK2350047T3 true DK2350047T3 (da)	2013-09-30

Family

ID=40019929

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09736271.9T DK2350047T3 (da)	2008-10-02	2009-10-02	p38-MAP-KINASEINHIBITORER

Country Status (34)

Country	Link
US (1)	US8293771B2 (da)
EP (1)	EP2350047B1 (da)
JP (1)	JP5571088B2 (da)
KR (1)	KR101660266B1 (da)
CN (1)	CN102203078B (da)
AU (1)	AU2009299554B8 (da)
BR (1)	BRPI0920840A2 (da)
CA (1)	CA2738827C (da)
CL (1)	CL2011000735A1 (da)
CO (1)	CO6351785A2 (da)
CR (1)	CR20110230A (da)
CY (1)	CY1114665T1 (da)
DK (1)	DK2350047T3 (da)
EA (1)	EA019590B1 (da)
EC (1)	ECSP11010948A (da)
ES (1)	ES2428917T3 (da)
GB (1)	GB0818033D0 (da)
HK (1)	HK1157781A1 (da)
HN (1)	HN2011000874A (da)
HR (1)	HRP20130895T1 (da)
ME (1)	ME01604B (da)
MX (1)	MX2011003552A (da)
MY (1)	MY150611A (da)
NI (1)	NI201100062A (da)
NZ (1)	NZ591426A (da)
PE (1)	PE20110810A1 (da)
PL (1)	PL2350047T3 (da)
PT (1)	PT2350047E (da)
RS (1)	RS52979B (da)
SI (1)	SI2350047T1 (da)
SM (1)	SMT201300097B (da)
UA (2)	UA104731C2 (da)
WO (1)	WO2010038085A2 (da)
ZA (1)	ZA201103181B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009077766A1 (en)	2007-12-19	2009-06-25	Cancer Research Technology Limited	Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
KR20110070887A (ko) *	2008-10-02	2011-06-24	레스피버트 리미티드	Ｐ38 엠에이피 키나제 억제제
KR20110094130A (ko) *	2008-12-11	2011-08-19	레스피버트 리미티드	Ｐ38 ｍａｐ 키나제 억제제
GB0905955D0 (en)	2009-04-06	2009-05-20	Respivert Ltd	Novel compounds
EP2236505A1 (de) *	2009-04-03	2010-10-06	Bayer CropScience AG	Acylierte Aminopyridine und - pyridazine als Insektizide
GB0921730D0 (en) *	2009-12-11	2010-01-27	Respivert Ltd	Method of treatment
ES2469367T3 (es)	2010-02-01	2014-06-18	Cancer Research Technology Limited	1-(5-Terc-butil-2-fenil-2H-pirazol-3-il)-3-[2-fluoro-4-(1-metil-2-oxo-2,3-dihidro-1H-imidazo[4,5-b]piridin-7-iloxi)-fenil]-urea y compuestos relacionados y su uso en terapia
GB201005589D0 (en)	2010-04-01	2010-05-19	Respivert Ltd	Novel compounds
JP5787977B2 (ja)	2010-04-08	2015-09-30	レスピバート・リミテツド	Ｐ３８ｍａｐキナーゼ阻害剤
JP5787976B2 (ja)	2010-04-08	2015-09-30	レスピバート・リミテツド	Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア
GB201010196D0 (en) *	2010-06-17	2010-07-21	Respivert Ltd	Methods
GB201010193D0 (en) *	2010-06-17	2010-07-21	Respivert Ltd	Medicinal use
WO2011158044A2 (en)	2010-06-17	2011-12-22	Respivert Limited	Respiratory formulations and compounds for use therein
EP2578582A1 (en)	2011-10-03	2013-04-10	Respivert Limited	1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
PL2763984T3 (pl)	2011-10-03	2016-10-31		1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP
US9458154B2 (en) *	2011-12-09	2016-10-04	Chiesi Farmaceutici S.P.A.	Kinase inhibitors
GB201214750D0 (en)	2012-08-17	2012-10-03	Respivert Ltd	Compounds
GB201215357D0 (en)	2012-08-29	2012-10-10	Respivert Ltd	Compounds
WO2014033447A2 (en)	2012-08-29	2014-03-06	Respivert Limited	Kinase inhibitors
WO2014033446A1 (en)	2012-08-29	2014-03-06	Respivert Limited	Kinase inhibitors
US9783556B2 (en)	2012-08-29	2017-10-10	Respivert Limited	Kinase inhibitors
US9732063B2 (en)	2012-11-16	2017-08-15	Respivert Limited	Kinase inhibitors
US20160016934A1 (en)	2013-03-14	2016-01-21	Respivert Limited	Kinase inhibitors
WO2014162121A1 (en)	2013-04-02	2014-10-09	Topivert Pharma Limited	Kinase inhibitors based upon n-alkyl pyrazoles
CN105246884B (zh)	2013-04-02	2018-05-22	瑞斯比维特有限公司	用作激酶抑制剂的脲衍生物
GB201320729D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Therapeutic compounds and their use
GB201320732D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Methods of chemical synthesis
CA2934199A1 (en)	2013-12-20	2015-06-25	Respivert Limited	Urea derivatives useful as kinase inhibitors
TWI751099B (zh)	2014-02-14	2022-01-01	英商瑞斯比維特有限公司	作為激酶抑制劑之吡唑基脲，包含其之製藥組成物及其用途
MA40775A (fr)	2014-10-01	2017-08-08	Respivert Ltd	Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
CN109071505B (zh)	2016-04-06	2021-11-16	奥苏拉收购有限公司	激酶抑制剂
GB201611712D0 (en) *	2016-07-02	2016-08-17	Hvivo Services Ltd	Methods and compounds for the treatment or prevention of severe or persistent influenza
GB201721793D0 (en)	2017-12-22	2018-02-07	Hvivo Services Ltd	Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
EP3802525A4 (en)	2018-05-30	2022-06-29	Washington University	Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
KR20240058628A (ko) *	2022-10-26	2024-05-07	(의료)길의료재단	신규화합물 및 이를 유효성분으로 포함하는 폐섬유화증 예방 또는 치료용 약학 조성물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001521934A (ja)	1997-11-03	2001-11-13	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	抗炎症薬としての芳香族ヘテロ環式化合物
US7329670B1 (en)	1997-12-22	2008-02-12	Bayer Pharmaceuticals Corporation	Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080300281A1 (en)	1997-12-22	2008-12-04	Jacques Dumas	Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
AU765412B2 (en)	1997-12-22	2003-09-18	Bayer Healthcare Llc	Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
ATE346600T1 (de)	1997-12-22	2006-12-15	Bayer Pharmaceuticals Corp	Inhibierung der p38 kinase-aktivität durch die verwendung von aryl- und heteroarylsubstituierten harnstoffen
ATE529109T1 (de)	1997-12-22	2011-11-15	Bayer Healthcare Llc	Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
EP1064289A1 (en)	1998-03-18	2001-01-03	Ariad Pharmaceuticals, Inc.	Heterocyclic signal transduction inhibitors, compositions containing them
UA73492C2 (en) *	1999-01-19	2005-08-15		Aromatic heterocyclic compounds as antiinflammatory agents
ATE312823T1 (de)	1999-07-09	2005-12-15	Boehringer Ingelheim Pharma	Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
US6525046B1 (en) *	2000-01-18	2003-02-25	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as antiinflammatory agents
MXPA03006749A (es)	2001-02-15	2004-05-31	Boehringer Ingelheim Pharma	Proceso para la sintesis de compuestos de urea sustituidos con heteroarilo, utiles como agentes antiinflamatorios.
CA2445003A1 (en)	2001-05-16	2002-11-21	Boehringer Ingelheim Pharmaceuticals, Inc.	Diarylurea derivatives useful as anti-inflammatory agents
DE60219793T2 (de)	2001-07-11	2008-01-24	Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield	Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen
AU2003210969A1 (en) *	2002-02-11	2003-09-04	Bayer Corporation	Aryl ureas with raf kinase and angiogenesis inhibiting activity
WO2003068228A1 (en)	2002-02-11	2003-08-21	Bayer Pharmaceuticals Corporation	Aryl ureas with angiogenesis inhibiting activity
US7041669B2 (en) *	2002-02-25	2006-05-09	Boehringer Ingelheim Pharmaceuticals, Inc.	1,4-benzofused urea compounds useful in treating cytokine mediated diseases
IL163737A0 (en)	2002-04-05	2005-12-18	Boehringer Ingelheim Pharma	Method of treating mucus hypersecretion
US20040110755A1 (en)	2002-08-13	2004-06-10	Boehringer Ingelheim Pharmaceuticals, Inc.	Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
CA2497951A1 (en)	2002-09-05	2004-03-18	Scios Inc.	Treatment of pain by inhibition of p38 map kinase
US7144911B2 (en)	2002-12-31	2006-12-05	Deciphera Pharmaceuticals Llc	Anti-inflammatory medicaments
US7202257B2 (en)	2003-12-24	2007-04-10	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
MXPA05009103A (es)	2003-02-28	2006-04-18	Bayer Pharmaceuticals Corp	Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios.
WO2004078116A2 (en)	2003-03-03	2004-09-16	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
GB0308511D0 (en)	2003-04-14	2003-05-21	Astex Technology Ltd	Pharmaceutical compounds
GB0320244D0 (en)	2003-05-06	2003-10-01	Aventis Pharma Inc	Pyrazoles as inhibitors of tumour necrosis factor
JPWO2004101529A1 (ja)	2003-05-19	2006-07-13	小野薬品工業株式会社	含窒素複素環化合物およびその医薬用途
US20050148555A1 (en)	2003-08-22	2005-07-07	Boehringer Ingelheim Pharmaceuticals, Inc.	Methods of treating COPD and pulmonary hypertension
CA2545711A1 (en)	2003-11-13	2005-06-02	Ambit Biosciences Corporation	Urea derivatives as kinase modulators
EP1755607A2 (en)	2004-04-29	2007-02-28	Pharmix Corporation	Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
CA2564325A1 (en)	2004-04-30	2005-11-24	Bayer Pharmaceuticals Corporation	Substituted pyrazolyl urea derivatives useful in the treatment of cancer
KR20070032648A (ko)	2004-05-12	2007-03-22	브리스톨-마이어스 스큅 컴퍼니	혈전 상태의 치료에 유용한 ｐ２ｙ１ 수용체의 우레아길항제
US7767674B2 (en)	2004-06-23	2010-08-03	Eli Lilly And Company	Kinase inhibitors
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
GB0423554D0 (en)	2004-10-22	2004-11-24	Cancer Rec Tech Ltd	Therapeutic compounds
EP1824843A2 (en)	2004-12-07	2007-08-29	Locus Pharmaceuticals, Inc.	Inhibitors of protein kinases
JP2008524213A (ja)	2004-12-20	2008-07-10	アストラゼネカ・アクチエボラーグ	新規なピラゾール誘導体及びニコチン性アセチルコリン受容体のモジュレーターとしてのそれらの使用
EP1835934A4 (en)	2004-12-23	2010-07-28	Deciphera Pharmaceuticals Llc	ENZYME MODULATORS AND TREATMENTS
US20090312349A1 (en)	2004-12-23	2009-12-17	Deciphera Pharmaceuticals, Llc	Anti-inflammatory medicaments
GB0500435D0 (en) *	2005-01-10	2005-02-16	Novartis Ag	Organic compounds
DE102005015253A1 (de)	2005-04-04	2006-10-05	Merck Patent Gmbh	Pyrazolderivate
EP1899299B1 (en)	2005-06-27	2010-10-20	Bristol-Myers Squibb Company	C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
DE102005037499A1 (de)	2005-08-09	2007-02-15	Merck Patent Gmbh	Pyrazolderivate
WO2007038425A2 (en)	2005-09-27	2007-04-05	Regents Of The University Of Minnesota	Anti-viral compouinds
EP1960394A2 (en)	2005-11-15	2008-08-27	Bayer HealthCare AG	Pyrazolyl urea derivatives useful in the treatment of cancer
US20110195110A1 (en)	2005-12-01	2011-08-11	Roger Smith	Urea compounds useful in the treatment of cancer
CA2659971A1 (en)	2006-08-04	2008-02-07	Takeda Pharmaceutical Company Limited	Fused heterocyclic derivative and use thereof
KR101510356B1 (ko) *	2008-07-31	2015-04-06	휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피.	광학 신호들을 증폭, 변조 및 검출하기 위한 나노-와이어 광학 블록 디바이스들
KR20110070887A (ko) *	2008-10-02	2011-06-24	레스피버트 리미티드	Ｐ38 엠에이피 키나제 억제제
KR20110094130A (ko) *	2008-12-11	2011-08-19	레스피버트 리미티드	Ｐ38 ｍａｐ 키나제 억제제

2008
- 2008-10-02 GB GBGB0818033.3A patent/GB0818033D0/en not_active Ceased
2009
- 2009-10-02 PE PE2011000798A patent/PE20110810A1/es not_active Application Discontinuation
- 2009-10-02 EP EP09736271.9A patent/EP2350047B1/en active Active
- 2009-10-02 UA UAA201103554A patent/UA104731C2/ru unknown
- 2009-10-02 DK DK09736271.9T patent/DK2350047T3/da active
- 2009-10-02 MX MX2011003552A patent/MX2011003552A/es active IP Right Grant
- 2009-10-02 EA EA201170520A patent/EA019590B1/ru not_active IP Right Cessation
- 2009-10-02 RS RS20130407A patent/RS52979B/en unknown
- 2009-10-02 US US13/121,445 patent/US8293771B2/en active Active
- 2009-10-02 BR BRPI0920840-2A patent/BRPI0920840A2/pt not_active Application Discontinuation
- 2009-10-02 WO PCT/GB2009/051303 patent/WO2010038085A2/en active Application Filing
- 2009-10-02 MY MYPI20111436 patent/MY150611A/en unknown
- 2009-10-02 CN CN200980139617.9A patent/CN102203078B/zh active Active
- 2009-10-02 UA UAA201103555A patent/UA105014C2/uk unknown
- 2009-10-02 PL PL09736271T patent/PL2350047T3/pl unknown
- 2009-10-02 ME MEP-2013-108A patent/ME01604B/me unknown
- 2009-10-02 PT PT97362719T patent/PT2350047E/pt unknown
- 2009-10-02 ES ES09736271T patent/ES2428917T3/es active Active
- 2009-10-02 SI SI200930725T patent/SI2350047T1/sl unknown
- 2009-10-02 JP JP2011529636A patent/JP5571088B2/ja active Active
- 2009-10-02 AU AU2009299554A patent/AU2009299554B8/en active Active
- 2009-10-02 NZ NZ591426A patent/NZ591426A/xx unknown
- 2009-10-02 KR KR1020117009956A patent/KR101660266B1/ko active IP Right Grant
- 2009-10-02 CA CA2738827A patent/CA2738827C/en active Active
2011
- 2011-03-25 CO CO11037006A patent/CO6351785A2/es active IP Right Grant
- 2011-04-01 EC EC2011010948A patent/ECSP11010948A/es unknown
- 2011-04-01 NI NI201100062A patent/NI201100062A/es unknown
- 2011-04-01 CL CL2011000735A patent/CL2011000735A1/es unknown
- 2011-04-01 HN HN2011000874A patent/HN2011000874A/es unknown
- 2011-04-29 ZA ZA2011/03181A patent/ZA201103181B/en unknown
- 2011-05-02 CR CR20110230A patent/CR20110230A/es unknown
- 2011-11-16 HK HK11112365.9A patent/HK1157781A1/xx unknown
2013
- 2013-09-05 SM SM201300097T patent/SMT201300097B/xx unknown
- 2013-09-20 HR HRP20130895AT patent/HRP20130895T1/hr unknown
- 2013-09-25 CY CY20131100835T patent/CY1114665T1/el unknown

Also Published As

Publication number	Publication date
NZ591426A (en)	2012-12-21
HRP20130895T1 (en)	2013-10-25
HN2011000874A (es)	2014-02-03
UA104731C2 (ru)	2014-03-11
UA105014C2 (uk)	2014-04-10
CA2738827A1 (en)	2010-04-08
ZA201103181B (en)	2012-10-31
JP2012504590A (ja)	2012-02-23
SI2350047T1 (sl)	2013-11-29
ECSP11010948A (es)	2011-06-30
PE20110810A1 (es)	2011-11-08
SMT201300097B (it)	2013-11-08
AU2009299554B8 (en)	2013-12-12
ES2428917T3 (es)	2013-11-12
CY1114665T1 (el)	2016-10-05
EA019590B1 (ru)	2014-04-30
EP2350047A2 (en)	2011-08-03
KR101660266B1 (ko)	2016-09-27
WO2010038085A3 (en)	2010-06-24
AU2009299554B2 (en)	2013-11-21
CO6351785A2 (es)	2011-12-20
MX2011003552A (es)	2011-05-25
GB0818033D0 (en)	2008-11-05
AU2009299554A1 (en)	2010-04-08
CN102203078A (zh)	2011-09-28
PL2350047T3 (pl)	2013-12-31
US20110269800A1 (en)	2011-11-03
CA2738827C (en)	2017-02-28
EA201170520A1 (ru)	2011-12-30
US8293771B2 (en)	2012-10-23
BRPI0920840A2 (pt)	2020-10-20
CN102203078B (zh)	2014-06-25
MY150611A (en)	2014-01-30
EP2350047B1 (en)	2013-06-26
CR20110230A (es)	2011-11-10
KR20110065544A (ko)	2011-06-15
WO2010038085A2 (en)	2010-04-08
HK1157781A1 (en)	2012-07-06
PT2350047E (pt)	2013-10-01
CL2011000735A1 (es)	2011-10-14
ME01604B (me)	2014-09-20
NI201100062A (es)	2011-10-21
RS52979B (en)	2014-02-28
JP5571088B2 (ja)	2014-08-13

Publication	Publication Date	Title
DK2350047T3 (da)	2013-09-30	p38-MAP-KINASEINHIBITORER
CY2019009I2 (el)	2019-11-27	Αναστολεις πρωτεϊνικων κινασων
BRPI0922962A2 (pt)	2019-09-24	inibidores de p38 map quinase
CY2019027I1 (el)	2019-11-27	Παραγωγα φωσφορου ως αναστολεις κινασης
CY2020024I1 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
HK1160129A1 (en)	2012-08-10	P38 map kinase inhibitors p38 map
CY2017016I2 (el)	2017-07-12	Αναστολεις πρωτεασωματος
DK2247592T3 (da)	2011-09-26	Pyrrolopyrazinkinaseinhibitors
ATE519763T1 (de)	2011-08-15	Pyrrolopyrazin-kinasehemmer
DK2013175T5 (da)	2020-12-21	p38 Map-kinase-inhibitorer
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
BRPI0910668A2 (pt)	2019-09-24	inibidores de proteína quinases
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0820544A2 (pt)	2015-06-16	4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0811212A2 (pt)	2014-10-29	Inibidores de p70 quinase
BRPI0814797A2 (pt)	2015-02-03	Inibidores dna-pk
BRPI0918564A2 (pt)	2015-12-01	inibidores
BRPI1005327A2 (pt)	2019-09-24	derivados de triazolopiridina como inibidores de p38 map quinase
BRPI0716198A2 (pt)	2013-11-12	Pirrolo-isoquinolinas como inibidores de cinase
DK2170891T3 (da)	2011-12-12	Pyrazolopyrimidinon-kinasehæmmere
BRPI0719883A2 (pt)	2015-05-05	Inibidores de quinase
LTC2379528I2 (lt)	2019-11-25	Baltymų kinazės slopikliai
ZA200809361B (en)	2009-08-26	p38 MAP kinase inhibitors
BRPI0907574A2 (pt)	2015-07-21	Inibidores de ligação de proteína quinase